Status: Currently Official on 17-Feb-2025
Official Date: Official as of 01-Aug-2017
Document Type: USP Monographs
DocId: GUID-6644E114-1841-4D48-9C9E-3FBE20AC3DD7_1_en-US
DOI: https://doi.org/10.31003/USPNF_M8102_01_01
DOI Ref: bai3n

© 2025 USPC Do not distribute

Benzocaine, Butamben, and Tetracaine Hydrochloride Topical Aerosol

DEFINITION

Benzocaine, Butamben, and Tetracaine Hydrochloride Topical Aerosol is Benzocaine, Butamben, and Tetracaine Hydrochloride Topical Solution packaged in a pressurized container with a suitable inert propellant. It contains NLT 90.0% and NMT 110.0% of the labeled amount of benzocaine $(C_0H_1NO_2)$, butamben $(C_1H_2NO_2)$, and tetracaine hydrochloride $(C_1H_2NO_2)$.

IDENTIFICATION

- A. The retention times of the major peaks of the Sample solution correspond to those of the Standard solution, as obtained in the Assay.
- B. The UV spectrum of the major peaks of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

• PROCEDURE

Solution A: 0.1% <u>formic acid</u> in <u>water</u> **Solution B:** 0.1% <u>formic acid</u> in acetonitrile

Mobile phase: See <u>Table 1</u>.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	91	9
2.5	50	50
3.9	50	50
4	91	9
5	91	9

Diluent: Acetonitrile and water (10:90)

Standard stock solution A: 1750 μg/mL of <u>USP Benzocaine RS</u> prepared as follows. Transfer a suitable amount of <u>USP Benzocaine RS</u> to a suitable volumetric flask and dissolve in 10% of the total volume of <u>acetonitrile</u>. Dilute with <u>water</u> to volume.

Standard stock solution B: 250 µg/mL each of <u>USP Butamben RS</u> and <u>USP Tetracaine Hydrochloride RS</u> prepared as follows. Transfer a suitable amount of <u>USP Butamben RS</u> and <u>USP Tetracaine Hydrochloride RS</u> to a suitable volumetric flask and dissolve in 10% of the total volume of <u>acetonitrile</u>. Dilute with <u>water</u> to volume.

Standard solution: 175 μg/mL of <u>USP Benzocaine RS</u> from Standard stock solution A and 25 μg/mL each of <u>USP Butamben RS</u> and <u>USP Tetracaine Hydrochloride RS</u> from Standard stock solution B diluted in Diluent

Sample solution: Nominally 175 μg/mL of benzocaine and 25 μg/mL each of butamben and tetracaine hydrochloride, prepared as follows.

Accurately weigh about 125 mg of the evaporated sample into a 100-mL volumetric flask. Dissolve in 50 mL of methanol and dilute with Diluent to volume.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 300 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

Column: 2.1-mm × 5-cm; 1.7-µm packing L1

Flow rate: 0.6 mL/min Injection volume: 1 μL System suitability

Sample: Standard solution

[Note—The relative retention times for benzocaine, tetracaine, and butamben are about 0.71, 0.74, and 1.0, respectively.]

Suitability requirements

https://trungtamthuoc.com/

Resolution: NLT 2 between benzocaine and tetracaine

Relative standard deviation: NMT 2.0% for each of the three analyte peaks

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of benzocaine ($C_9H_{11}NO_2$), butamben ($C_{11}H_{15}NO_2$), and tetracaine hydrochloride ($C_{15}H_{24}N_2O_2 \cdot HCI$) in the portion of Topical Aerosol taken:

Result =
$$(r_{IJ}/r_{S}) \times (C_{S}/C_{IJ}) \times 100$$

 r_{ij} = peak response of the corresponding analyte from the Sample solution

 r_s = peak response of the corresponding analyte from the Standard solution

 C_s = concentration of the corresponding Reference Standard in the Standard solution (μ g/mL)

 C_{μ} = nominal concentration of the corresponding analyte in the Sample solution (µg/mL)

Acceptance criteria: 90.0%-110.0%

PERFORMANCE TESTS

• MINIMUM FILL (755): Meets the requirements

IMPURITIES

• ORGANIC IMPURITIES

Mobile phase, Diluent, and Chromatographic system: Proceed as directed in the Assay.

System suitability solution: 10 µg/mL each of <u>USP Benzocaine RS</u>, <u>USP Tetracaine Hydrochloride RS</u>, <u>USP Butamben RS</u>, and <u>USP Ethyl 4-Nitrobenzoate RS</u> in *Diluent*

Standard solution: 3.4 µg/mL each of <u>USP Benzocaine RS</u> and <u>USP Ethyl 4-Nitrobenzoate RS</u> and 1 µg/mL of <u>USP Tetracaine Hydrochloride</u> <u>RS</u> in *Diluent*

Sample solution: Nominally 1.68 mg/mL of benzocaine, 0.24 mg/mL of butamben, and 0.24 mg/mL of tetracaine prepared as follows.

Accurately weigh about 600 mg of evaporated sample into a 50-mL volumetric flask, dissolve with 25 mL of methanol, and dilute with Diluent to volume. [Note—Sonication for about 1 min may be necessary.]

System suitability

Samples: System suitability solution and Standard solution

[Note—See <u>Table 2</u> for relative retention times.]

Suitability requirements

Resolution: NLT 2 between butamben and ethyl 4-nitrobenzoate; NLT 2 between benzocaine and tetracaine, *System suitability solution* **Relative standard deviation:** NMT 5.0% for each of the analyte peaks, *Standard solution*

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of 4-aminobenzoic acid in the portion of Topical Aerosol taken:

Result =
$$(r_{II}/r_{S}) \times (C_{S}/C_{II}) \times (1/F) \times 100$$

r, = peak response of 4-aminobenzoic acid from the Sample solution

 $r_{\rm s}$ = peak response of benzocaine from the Standard solution

 C_s = concentration of <u>USP Benzocaine RS</u> in the Standard solution (µg/mL)

 $C_{_U}$ = nominal concentration of benzocaine in the Sample solution (µg/mL)

F = relative response factor (see <u>Table 2</u>)

Calculate the percentage of ethyl 4-nitrobenzoate in the portion of Topical Aerosol taken:

Result =
$$(r_U/r_S) \times (C_S/C_U) \times 100$$

 $r_{_U}$ = peak response of ethyl 4-nitrobenzoate from the Sample solution

 r_s = peak response of ethyl 4-nitrobenzoate from the Standard solution

C_s = concentration of <u>USP Ethyl 4-Nitrobenzoate RS</u> in the Standard solution (µg/mL)

 $C_{\mu\nu}$ = nominal concentration of benzocaine in the Sample solution (µg/mL)

https://trungtamthuoc.com/

Calculate the percentage of tetracaine related compound B and any individual unspecified degradation product in the portion of Topical Aerosol taken:

Result =
$$(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

= peak response of tetracaine related compound B or any individual unspecified degradation product from the Sample solution

= peak response of tetracaine from the Standard solution

= concentration of <u>USP Tetracaine Hydrochloride RS</u> in the Standard solution (µg/mL)

= nominal concentration of tetracaine hydrochloride in the Sample solution (µg/mL)

= relative response factor (see <u>Table 2</u>)

Acceptance criteria: See <u>Table 2</u>. Disregard any impurity peaks less than 0.05%.

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
4-Aminobenzoic acid	0.15	1.3	0.3
Benzocaine	0.70	-	_
Tetracaine	0.74	-	-
Tetracaine related compound B ^a	0.93	0.6	0.4
Butamben	1.0	-	-
Ethyl 4-nitrobenzoate	1.04	-	0.2
Any individual unspecified degradation product		1.0	0.4
Total degradation products		-	2.0

^a 4-(Butylamino)benzoic acid.

SPECIFIC TESTS

- Topical Aerosols (603), Pressure Test: Meets the requirements
- LEAK RATE (604): Meets the requirements

ADDITIONAL REQUIREMENTS

- · Packaging and Storage: Preserve in pressurized containers, and avoid exposure to excessive heat.
- USP REFERENCE STANDARDS (11)

USP Benzocaine RS USP Butamben RS

USP Ethyl 4-Nitrobenzoate RS

Ethyl p-nitrobenzoate.

C₉H₉NO₄

USP Tetracaine Hydrochloride RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL AEROSOL	Documentary Standards Support	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	SM52020 Small Molecules 5

Chromatographic Database Information: <u>Chromatographic Database</u>

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 42(3)

Current DocID: GUID-6644E114-1841-4D48-9C9E-3FBE20AC3DD7_1_en-US

DOI: https://doi.org/10.31003/USPNF_M8102_01_01

DOI ref: bai3n